Utilizing proteomic strategies to uncover novel biomarkers and mechanisms in heart failure
Utilizing proteomic strategies to uncover novel biomarkers and mechanisms in heart failure
Plasma proteomics is a powerful approach for discovering novel protein biomarkers of drug toxicity in various disease contexts. One such biomarker in cardiovascular disease is apolipoprotein M (ApoM), which plays a crucial role in lipid metabolism and transport and is known to have both anti-inflammatory and cardioprotective effects in the body. Studying ApoM using proteomics requires various approaches to understand its expression, modifications, interactions, and functions in the proteome.
Learn about:
- Association between ApoM and heart failure outcomes
- Effects of the chemotherapeutic drug doxorubicin on ApoM levels
- How ApoM heterozygosity affects the regulation of transcription factor EB
Ali Javaheri, MD
Assistant Professor, Medicine, Cardiovascular Division
Washington University School of Medicine in St. Louis
Ali Javaheri, MD, is Assistant Professor of Medicine and Investigator in the Center for Cardiovascular Research at Washington University in St. Louis, and broadly trained in multiple disciplines. His clinical expertise and training is in advanced heart failure, a syndrome with no cure that has a worse prognosis than many cancers (5 year 50% mortality). He has led and contributed to studies that have utilized proteomic strategies to uncover the importance of novel pathways in human heart failure. These studies have highlighted the important role of apolipoprotein M (ApoM). Reduced circulating ApoM is associated with poor prognosis in heart failure. Dr. Javaheri shows the ApoM-content of isolated high-density lipoprotein correlates strongly with its sphingosine-1-phosphate content; however, adjusting for sphingosine-1-phosphate levels only partially attenuated the association between ApoM and heart failure survival. Together with Dr. Mahmoud Nasr at Harvard Medical School, Dr. Javaheri recently filed a provisional patent for nanotherapies related to ApoM. His ongoing studies on ApoM suggest significant translational potential for this pathway in heart failure.
Utilizing proteomic strategies to uncover novel biomarkers and mechanisms in heart failure
A presentation by Ali Javaheri, MD
More webinars
WebinarRethinking Neurodegeneration Through Blood-Based Biomarkers
Proteomics is reshaping how we predict, diagnose, and understand neurodegenerative diseases. In this roundtable, leading experts Tony Wyss-Coray, PhD, and Jacob Vogel, PhD, explore the power of blood-based biomarkers, from deep molecular studies to global-scale datasets using the SomaScan™ Assay. They discuss how protein signatures can reveal brain aging, predict dementia, and track changes in disease pathways over time, with moderation by Steve Williams, MD, PhD. Learn how cutting-edge proteomics is redefining what is possible in neurological research.
WebinarProteomics in Clinical Trials: Lessons from Semaglutide Treatment in Individuals with Obesity
Advancements in proteomic profiling have opened new avenues for understanding the complex mechanisms underlying obesity and its comorbidities. By measuring thousands of proteins at once, researchers gain a comprehensive view of an individual’s metabolic health, revealing subclinical processes and pinpointing potential therapeutic targets.
WebinarPathways to Digital Health: AI and Omics in Rheumatoid Arthritis
Explore how groundbreaking proteomic research is transforming our understanding of rheumatoid arthritis (RA). In this on-demand webinar, Allan Stensballe, PhD, shares new insights into the molecular landscape of RA-affected synovial tissue, revealing how autoantibodies and protein signatures may hold the key to more precise personalized therapies.